Health Technology · Pharmaceuticals: Major · NSE: KREBSBIO · data 2026-10-09
Krebs Biochemicals & Industries Ltd.
Health check: Weak (1.2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹56
Market cap
₹125 cr
P/E
—
P/B
—
ROE
—
ROCE
-17.3%
Debt / equity
—
Dividend yield
0.00%
1-year return
-20.6%
52-week high
₹76.85
52-week low
₹38.33
Operating margin
-35.5%
Growth
| Revenue (last 12 months) | ₹25 cr |
| Net profit (last 12 months) | ₹-14 cr |
| Sales growth, 3 years (yearly) | -23.3% |
| Profit growth, 3 years (yearly) | — |
Similar companies
Bal Pharma Limited (BALPHARMA) · Quest Laboratories Ltd. (QUESTLAB) · Parnax Lab Limited (PARNAXLAB) · Alpa Laboratories Limited (ALPA) · Makers Laboratories Ltd (MAKERSL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KREBSBIO in NSE Scanner →